NOTCH1, SF3B1, BIRC3andTP53mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
NOTCH1, SF3B1, BIRC3andTP53mutations in patients with chronic lymphocytic leukemia undergoing first-line treatment: correlation with biological parameters and response to treatment
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume 55, Issue 12, Pages 2785-2792
Publisher
Informa UK Limited
Online
2014-03-06
DOI
10.3109/10428194.2014.898760
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- NOTCH1, SF3B1, and TP53 mutations in fludarabine-refractory CLL patients treated with alemtuzumab: results from the CLL2H trial of the GCLLSG
- (2013) A. Schnaiter et al. BLOOD
- TP53, SF3B1, and NOTCH1 mutations and outcome of allotransplantation for chronic lymphocytic leukemia: six-year follow-up of the GCLLSG CLL3X trial
- (2013) P. Dreger et al. BLOOD
- Clinical implications of the molecular genetics of chronic lymphocytic leukemia
- (2013) R. Foa et al. HAEMATOLOGICA
- Integrated mutational and cytogenetic analysis identifies new prognostic subgroups in chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- Disruption of BIRC3 associates with fludarabine chemorefractoriness in TP53 wild-type chronic lymphocytic leukemia
- (2012) D. Rossi et al. BLOOD
- The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial
- (2012) D. G. Oscier et al. BLOOD
- ERIC recommendations on TP53 mutation analysis in chronic lymphocytic leukemia
- (2012) S Pospisilova et al. LEUKEMIA
- NOTCH1 mutations in CLL associated with trisomy 12
- (2011) V. Balatti et al. BLOOD
- Mutations of the SF3B1 splicing factor in chronic lymphocytic leukemia: association with progression and fludarabine-refractoriness
- (2011) D. Rossi et al. BLOOD
- Mutations of NOTCH1 are an independent predictor of survival in chronic lymphocytic leukemia
- (2011) D. Rossi et al. BLOOD
- ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression
- (2011) A. Guarini et al. HAEMATOLOGICA
- NOTCH1 mutations in +12 chronic lymphocytic leukemia (CLL) confer an unfavorable prognosis, induce a distinctive transcriptional profiling and refine the intermediate prognosis of +12 CLL
- (2011) I. Del Giudice et al. HAEMATOLOGICA
- Mutational Status of theTP53Gene As a Predictor of Response and Survival in Patients With Chronic Lymphocytic Leukemia: Results From the LRF CLL4 Trial
- (2011) David Gonzalez et al. JOURNAL OF CLINICAL ONCOLOGY
- Analysis of the chronic lymphocytic leukemia coding genome: role ofNOTCH1mutational activation
- (2011) Giulia Fabbri et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia
- (2011) Víctor Quesada et al. NATURE GENETICS
- SF3B1and Other Novel Cancer Genes in Chronic Lymphocytic Leukemia
- (2011) Lili Wang et al. NEW ENGLAND JOURNAL OF MEDICINE
- NOTCH1 PEST domain mutation is an adverse prognostic factor in B-CLL
- (2010) Paolo Sportoletti et al. BRITISH JOURNAL OF HAEMATOLOGY
- White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia
- (2010) I. Del Giudice et al. HAEMATOLOGICA
- TP53Mutation and Survival in Chronic Lymphocytic Leukemia
- (2010) Thorsten Zenz et al. JOURNAL OF CLINICAL ONCOLOGY
- Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial
- (2010) M Hallek et al. LANCET
- The Prognostic Value of TP53 Mutations in Chronic Lymphocytic Leukemia Is Independent of Del17p13: Implications for Overall Survival and Chemorefractoriness
- (2009) D. Rossi et al. CLINICAL CANCER RESEARCH
- Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group
- (2009) Stephan Stilgenbauer et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now